Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

151 results about "Methylcyclopropane" patented technology

Methylcyclopropane is an organic compound with the structural formula C₃H₅CH₃. This colorless gas is the monomethyl derivative of cyclopropane.

Method for purifying 2, 2-dimethyl-cyclopropane carboxamide produced by biocatalytic method

The invention relates to a method for purifying 2, 2-dimethyl-cyclopropane carboxamide produced by biocatalytic method. The method comprises: (1) conversion solution containing the 2, 2-dimethyl-cyclopropane carboxamide removes impurities by centrifugation or a membrane filtration system, so as to obtain supernatant fluid; (2) activated carbon which is 1-10 per mill of the quality of the supernatant fluid is added, and the decolorization of the activated carbon is carried out at 40-80 DEG C; (3) the pH value of the supernatant fluid after the decolorization is regulated to 8.5-13.5, macroporous adsorption resin is used for absorption till the supernatant fluid is saturated, the impurities are removed by water washing, hydrophilic solvent water solution with the volume concentration of 30-95 percent is further used for elution, the reduced pressure recovery of solvent and the concentration are carried out on eluent, so as to obtain a 2, 2-dimethyl-cyclopropane carboxamide crude product; (4) the 2, 2-dimethyl-cyclopropane carboxamide crude product is dissolved in hot water at 45-80 DEG C, stirred and crystallized at 0-4 DEG C, filtered and separated, and the 2, 2-dimethyl-cyclopropane carboxamide is finally obtained by drying crystals. The invention has the beneficial effects that the production process is simple and easy to operate, the product recovery rate is high and the industrial production is easy to realize.
Owner:ZHEJIANG UNIV OF TECH

Procymidone hapten and synthetic method and application thereof

The invention discloses a procymidone hapten and a synthetic method and application thereof. The synthetic method comprises the following steps: (1) alpha-chloromethyl acrylate and methyl methacrylateare used as starting materials to synthesize 1,2-dimethyl-1,2-cyclopropane dicarboxylic methyl ester; 1,2-dimethyl-1,2-cyclopropane dicarboxylic methyl ester undergoes hydrolysis and intramolecular condensation to generate 1,2-dimethylcyclopropane-1,2-dicarboxylic acid anhydride; (2) 3-chloro-5-nitrophenol and a compound 3 are used as raw materials to synthesize an intermediate with an arm, and the intermediate is subjected to a reduction reaction to obtain an intermediate B; and (3) 1,2-dimethylcyclopropane-1,2-dicarboxylic acid anhydride and the intermediate B undergo two times of condensation reaction for cyclization and one time of hydrolysis reaction to obtain the final target product. In the invention, characteristic structure of procymidone is retained in the synthesized procymidone hapten such that the immunogenicity of the procymidone hapten is obviously enhanced, and the procymidone hapten also has a carboxyl group capable of coupling with a carrier, thus providing a foundation for subsequently building various immunoassay methods of procymidone.
Owner:SHENZHEN BIOEASY BIOTECHNOLOGY CO LTD

Cell strain 16, monoclonal antibody produced by cell strain 16 and use of monoclonal antibody produced by cell strain 16

The invention relates to a cell strain 16, a monoclonal antibody produced by the cell strain 16 and a use of the monoclonal antibody produced by the cell strain 16. A preparation method of the cell strain 16 comprises the following steps of coupling hapten 1 (H1) 3-[cyano[cis-3-[2-chloro-3,3,3-trifluoroethyl-2, dimethyl]cyclopropane-phenoxy]phenylpropionic acid and hemocyanin KLH by an active ester method, coupling hapten 2 (H2) cyano-[3-(4-aminophenoxy)phenyl-cis-3-[2-chloro-3,3,3-trifluorovinyl-2,2-dimethyl]cyclopropionate and bovine serum albumin by a diazotization method to obtain a conjugate as a coating antigen, and carrying out animal immunization, serum determination, cell fusion, screening and subcloning to obtain the cell strain 16. Through a mouse internal ascites induced-production method, an ascitic fluid is produced, and then through a caprylic acid-ammonium sulfate precipitation method, the ascitic fluid is purified so that the corresponding monoclonal antibody is produced. The monoclonal antibody has high sensitivity, median inhibitory concentration (IC50) of 13.26+/-1.23ng/mL and strong singularity, provides a technology for detection of high-efficiency cyhalothrin residue in domestic agricultural products and has a good market prospect.
Owner:HENAN UNIV OF SCI & TECH

Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine

A pharmaceutical composition useful in the treatment of sneezing, itching runny nose, nasal congestion, redness of the eye, tearing, itching of the ears or palate, shortness of breath, inflammation of the bronchial mucosa, reduced Forced Expiratory Volume In One Second (FEV1), coughs, rash, itchy skin, headaches, and aches and pains associated with seasonal allergic rhinitis, perennial allergic rhinitis, common colds, otitis, sinusitus, allergy, asthma, allergic asthma and/or inflammation, in a mammalian organism in need of such treatment. The composition comprises: i) an effective amount of at least one leukotriene antagonist selected from a) montelukast, b) 1-(((R)- (3-(2-(6,7- difluoro-2- quinolinyl)ethenyl) phenyl)-3-(2- (2-hydroxy-2- propyl)phenyl) thio)methylcyclopropaneacetic acid; c) 1-(((1(R)-3 (3-(2-(2,3- dichlorothieno[3, 2-b]pyridin-5-yl) -(E)-ethenyl)phenyl) -3-(2-(1-hydroxy-1- methylethyl) phenyl)propyl) thio)methyl) cyclopropaneacetic acid; d) pranlukast; or f) [2-[[2-(4-tert -butyl-2-thiazolyl) -5-benzofuranyl] oxymethyl]phenyl] acetic acid; or a pharmaceutically acceptable salt thereof; in admixture with ii) an effective amount of at least one antihistamine which is descarboethoxyloratidine, cetirizine, fexofenadine, ebastine, astemizole, norastemizole, epinastine, efletirizine or a pharmaceutically acceptable salt thereof.
Owner:SCHERING AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products